 |
answer text |
<p>The Government wants patients to access cost-effective innovative medicines and
technologies, which may include emerging treatments for muscle-wasting conditions,
at a price that the National Health Service can afford. That is why we commissioned
the Accelerated Access Review, which reported in October last year. We are considering
the review’s recommendations and will respond in due course.</p><p> </p><p>As part
of the exit negotiations the Government will discuss with the European Union and Member
States how best to continue cooperation on medicine research and development and regulation
in the best interests of both the United Kingdom and the EU. It would not be appropriate
to pre-judge the outcome of the negotiations, but we are clear that whatever happens
NHS patients should have access to cost-effective life-changing treatments as soon
as possible.</p>
|
 |
